AlphAIalphai — Financial news for AI agents
yahoo.comAUG 66 min read

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

Original reporting
yahoo.com
Published Aug 6, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary — source image
Source · yahoo.com
Decision brief

The 30-second read

Med
01

Why it matters

Traders can update models using the maintained full-year revenue guidance ($390M–$410M) alongside the lowered U.S. procedure guidance (54,000–56,000) and the stated replacement-cycle expectations through 2027, plus WATER IV enrollment completion and FDA IDE approval for an AF study.

02

Market read

The key tradable inputs are the guidance split: revenue range held while U.S. procedure outlook was reduced, with the bull case anchored on HYDROS ASP strength and an accelerating replacement cycle.

03

What to watch

DTC pilots show a 2-4 month lag to procedures, so near-term volume may understate longer-run demand; also, gross margin normalization and tariff recovery could affect earnings quality into 2026.

Relevance 7/10Novelty 7/10Timing: post-market earnings call summary, guidance update for 2026

Background

This is a Q2 2026 earnings call summary for Procept BioRobotics, focused on HYDROS system adoption versus legacy AQUABEAM performance and clinical pipeline progress.

Market effects

Sector

Signals continued shift from legacy urology platforms to newer AI-enabled systems, which can influence read-across sentiment for medtech procedure-volume expectations.

Regional

U.S.-specific procedure guidance cut may weigh on near-term U.S. medtech procedure-volume sentiment.

Global

Limited direct global read-through beyond the company’s U.S. procedure and replacement-cycle narrative.

Counterpoint

What could challenge this read

The legacy AQUABEAM softness may be more than temporary disruption; if replacement cycle timing slips, the lowered procedure guidance could dominate despite maintained revenue guidance.

Key entities

  • company
    Procept BioRobotics Corporation

    Guidance update and operational commentary on HYDROS adoption, legacy AQUABEAM softness, and WATER IV clinical progress.

  • product_platform
    HYDROS

    New Aquablation system platform highlighted for stronger utilization and record ASPs.

  • product_platform
    AQUABEAM

    Legacy platform described as experiencing concentrated softness in certain accounts.

  • clinical_trial
    WATER IV

    280-patient trial with primary endpoint results expected in spring 2027.

  • clinical_trial
    WATER IV AF study

    FDA IDE approval received to expand the pipeline evaluating Aquablation versus active surveillance.

Read at source← All news

Related articles

JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min
AUG 6
$WPPMedAI 8/10

WPP Stock Soars 25% as Turnaround Finally Gains Traction

WPP reported Q2 results that were still weak but improved versus Q1, with like-for-like revenue less pass-through costs down 2.8% versus a 6.7% decline in Q1. First-half revenue less pass-through costs totaled $4.75 billion. First-half headline operating margin rose to 8.4% and adjusted net debt fell to $2.94 billion. WPP shares rose about 24.7% in U.S. trading.

yahoo.com4 min
AUG 6
$RDWMed

Why Redwire Stock Soared After Earnings

Redwire Corp. (RDW) shares rose about 11% after its Q2 results. The company reported a smaller-than-expected loss of $0.09 per share versus an expected $0.16, on revenue of $117 million versus $107.9 million. Redwire cited record revenue, 27.8% gross margin, and $542.1 million backlog, and forecast $450 million to $500 million sales for 2024.

fool.com3 min